en Gastroentrology Gastroentrology Original Article Original Article <span style="font-size:14px;"><span style="font-family:Times New Roman;"><span style="line-height:14pt"><b><i><span style="color:blue">Background</span></i></b><i><span style="color:blue">:</span></i> <i>Helicobacter pylori</i> (<i>H. pylori</i>) has infected about 50% of the world&rsquo;s population and it is the main cause for peptic ulcer, gastric adenocarcinoma and even a major cause for gastric MALT lymphoma.</span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Methods:</span></i></b> This study was performed in Mazandaran, Sari, situated in North of Iran. Three-hundred and twenty-eight adult patients with endoscopically approved gastric or duodenal ulcers or erosions and <i>H. pylori</i> infection were randomly divided into 2 groups to receive either 14 days PABT (Pantoprazole 40 mg, Amoxicillin 1 g, Bismuth 425 mg (all twice daily) and Tetracycline 500 mg four times a day) and PACM (Pantoprazole 40 mg, Amoxicillin 1g, Clarithromycin 500 mg, and Metronidazole 500 mg, all twice daily). To evaluate <i>H. pylori </i>eradication, fecal <i>H. pylori </i>antigen test was performed 8 weeks after treatment.<span style="font-size:10.0pt"></span></span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Results:</span></i></b> The eradication rates were 94.51% in the PATB and 91.46% in PACM group based on the intention to treat analysis. Moreover, the eradication rates were 95.58% and 92.72% according to per-protocol analysis, respectively. Also, both groups had very low rates of severe side effects.<span style="font-size:10.0pt"></span></span><br> <span style="line-height:14pt"><b><i><span style="color:blue">Conclusion</span></i></b><i><span style="color:blue">:</span></i> Regarding the ideal eradication rates achieved by both treatment groups and the low rates of severe side effects, both treatment protocols can be prescribed for H. pylori eradication in North of Iran.<span style="font-size:10.0pt"></span></span></span></span> Helicobacter pylori, Bismuth, tetracycline, concomitant, eradication 676 680 http://caspjim.com/browse.php?a_code=A-10-2206-2&slc_lang=en&sid=1 Arash Kazemi arash_6z@yahoo.com 100319475328460044916 100319475328460044916 No Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran Ali Rahimi Petrudi doc.ali.rahimi@gmail.com 100319475328460044917 100319475328460044917 No Mazandaran University of Medical Sciences, Sari, Iran Iradj Maleki iradj2001@yahoo.com 100319475328460044918 100319475328460044918 No Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran Hafez Fakheri hafezfakheri@gmail.com 100319475328460044919 100319475328460044919 No Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran Tarang Taghvaei tarang_taghvaei@yahoo.com 100319475328460044920 100319475328460044920 No Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran Vahid Hosseini dr.vahid47@gmail.com 100319475328460044921 100319475328460044921 No Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran Mohammad Valizadeh Toosi seyedmohammadv@yahoo.com 100319475328460044922 100319475328460044922 No Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran Danial Masoumi danialmasumi@yahoo.com 100319475328460044923 100319475328460044923 No Mazandaran University of Medical Sciences, Sari, Iran Zohreh Bari zohreb252@yahoo.com 100319475328460044924 100319475328460044924 Yes Gut and Liver Research Center, Non-communicable Disease Research Institute, Mazandaran University of Medical Sciences, Sari, Iran